We are live on ! Find out more
UTMD icon

Utah Medical Products

100 hedge funds and large institutions have $162M invested in Utah Medical Products in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

0% more funds holding

Funds holding: 100100 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

0.87% less ownership

Funds ownership: 69.36%68.49% (-0.87%)

9% less capital invested

Capital invested by funds: $177M → $162M (-$15.2M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
100
Holders Change
Holders Change %
0%
% of All Funds
1.44%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
20
Increased
39
Reduced
31
Closed
20
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$341K +$20.4K +300 +6%
ASN
52
Advisory Services Network
Georgia
$320K -$9.6K -141 -3%
Ameriprise
53
Ameriprise
Minnesota
$308K
SFA
54
Sequoia Financial Advisors
Ohio
$307K +$313K +4,597 New
Mercer Global Advisors
55
Mercer Global Advisors
Colorado
$291K -$681 -10 -0.2%
PIM
56
Penobscot Investment Management
Massachusetts
$267K
MAM
57
Martingale Asset Management
Massachusetts
$252K +$6.81K +100 +3%
Lazard Asset Management
58
Lazard Asset Management
New York
$251K +$147K +2,160 +135%
SCP
59
Seizert Capital Partners
Michigan
$242K -$33.7K -495 -12%
Bank of America
60
Bank of America
North Carolina
$236K +$126K +1,851 +110%
Cambridge Investment Research Advisors
61
Cambridge Investment Research Advisors
Iowa
$235K +$240K +3,519 New
Goldman Sachs
62
Goldman Sachs
New York
$207K -$313K -4,595 -60%
Aviva
63
Aviva
United Kingdom
$204K +$208K +3,060 New
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$188K +$105K +1,542 +121%
Victory Capital Management
65
Victory Capital Management
Texas
$179K +$101K +1,482 +124%
MIM
66
MetLife Investment Management
New Jersey
$147K +$11.7K +172 +8%
UBS Group
67
UBS Group
Switzerland
$132K -$111K -1,635 -45%
SOW
68
State of Wyoming
Wyoming
$123K +$125K +1,842 New
CF
69
Corebridge Financial
Texas
$122K +$124K +1,822 New
Mirae Asset Global ETFs Holdings
70
Mirae Asset Global ETFs Holdings
Hong Kong
$109K +$111K +1,627 New
Wells Fargo
71
Wells Fargo
California
$101K +$20.4K +300 +25%
Barclays
72
Barclays
United Kingdom
$97.3K -$76.4K -1,122 -44%
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$95.5K
Allspring Global Investments
74
Allspring Global Investments
North Carolina
$82.8K +$84.3K +1,239 New
Citigroup
75
Citigroup
New York
$81.5K +$42.2K +620 +103%

UTMD Hedge Fund Activity: Q2 2024 in Review

100 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q2 2024, worth a combined $162M — down 8.6% from $177M a quarter earlier.

Fund positioning in UTMD was balanced in Q2 2024: 20 funds opened new positions, 20 closed out, 39 added to existing stakes and 31 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $3.16M. The largest seller was Franklin Resources, exiting entirely with an estimated $2.99M sold.

  • 100 institutional investors held Utah Medical Products (UTMD) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $162M of Utah Medical Products stock for Q2 2024, down 8.6% quarter-over-quarter.
  • 20 funds opened new Utah Medical Products positions in Q2 2024 and 20 closed out, a net change of 0 holders.
  • The largest Utah Medical Products buyer in Q2 2024 was Brandes Investment Partners, an estimated $3.16M added.
  • The largest Utah Medical Products seller in Q2 2024 was Franklin Resources, an estimated $2.99M sold.

Based on aggregated 13F filings for Q2 2024.